

Reliable oncology RWE can be achieved through pan-network quality checks - Oncology Readiness Assessment standardized tools - CohortDiagnostics, ARTEMIS collaborative models - studyathon

A Large-Scale Network Study on the Impact of Immune Checkpoint Therapy in Metastatic Non-Small Cell Lung Cancer: The iCAN mNSCLC Studyathon

We conducted the largest federated oncology study to date with 30,153 non-small-cell lung cancer (NSCLC) patients from 17 data partners and 9 countries.




- The studyathon approach – an intensive, hybrid collaboration hosted in Helsinki in March 2025 – brought together a multidisciplinary team for a 4-day workshop.
- The studyathon model enabled the generation of results within three months of the initial call for participation

Initial results from the studyathon have been submitted:

- WCLC 2025 (*iCAN mNSCLC study-a-thon: A large-scale network study on the impact of immune checkpoint therapy*) (accepted)
- ESMO 2025 (*FALCON-Lung: Evolving global ICI treatment patterns and outcomes in personalized mNSCLC, and FALCON: A novel high-quality cancer network for real-world evidence*) (under review)

Oncology RWE studies face significant attrition, even with common cancers, requiring large federated networks



Participating required passing a novel, iterative data readiness and quality assessment pipeline

- 17/21 sites passed by the deadline (several sites will contribute results after the studyathon for the final analysis)
- Reliability of cohort definitions was assessed using
 1. OHDSI CohortDiagnostics [3]
 2. Additional cancer specific diagnostics by assessing changes in the disease trajectory from initial diagnosis to metastasis and treatment initiation.

Call For Data Partners

Readiness Script Execution → Assess Results → Data Patch

Query-assess-patch methodology

PASS

Studyathon Participation

FAIL



Details of the query-assess-patch-assess methodology in poster:

"Coordinating center-based, rather than self-deployed, data readiness assessment and improvement for oncology RWE"

iCAN
Digital Precision Cancer Medicine



Authors: Valtteri Nieminen (Presenter), Annelies Verbiest, Alayav Rytchenko, Stelios Theodorou, Geoff Hall, Thejas Bharadwaj, Jasmin Carus, Vagelis Chandakas, Elisavir Chase, Wei Hai Deng, Dmytro Dymalyts, Espen Enerly, Otto Ettala, Michael Franz, Katja Hoffmann, Mikael Höglman, Annelies Janssens, Tommi Kauko, Martin Koch, Sampu Kukkurainen, Harri Rantala, Carlos López Gómez, Álvaro Martínez Pérez, John Methot, Agnes Møvsgaard Eschen, Henry Morgan, Maria Eugenia Gas López, Parisa Movahedi, Tomi Mäkelä, Ghazalsh Nikiyani, Laura Perez, Christian Reich, Tom Stone, Ping Sun, Pia Tapinen-Doombouya, Zarah Van Schoor, Asa Ojert, Ilkka Ilonen, Paula Kauppi, Elad Sharon, Daniel Smith, Georgina Kennedy, Åsaug Helland, Eric Fej, Asish Golzari, Aja Kruuttila, Kimmo Porkka

REFERENCES

- [1] Artemis: Golzari A, Lawrence-Archer L, Zack T, Warner Z, Reich C. Introducing ARTEMIS: Advanced Regimen Detection Using an Adapted Smith-Waterman Algorithm. OHDSI 2023 Global Symposium 2023.
- [2] Nemura J, Dymalyts D, Reich CC, Gierke HJ, Hochhaus R, Hoffmann M, Böhmer J, Nieminen AE, Yang PC, HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OHDP common data model. J Biomed Inform. 2023;161:105239.
- [3] Gilbert S, Rous S, Schwenn M, Poon P, Winawer J. CohortDiagnostics: Diagnostics for OHDSI Cohorts. R package.